Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00166621|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : July 20, 2011
|Condition or disease||Intervention/treatment||Phase|
|Autism||Drug: Buspirone||Phase 1 Phase 2|
Autism is a neurodevelopmental disorder defined as qualitative impairment in social interaction and communication and restrictive stereotype patterns of behavior, interests and activities. Pharmacological agents are being increasingly used off label in very young autistic children, and there is virtually no data regarding the pharmacokinetics, safety or efficacy of these agents in young children.
The approach in this study differs from pharmacotherapy studies of autism carried out thus far in several ways:
- the rationale underlying our approach is based upon an attempt to alter synaptic plasticity during postnatal development, focusing on very young children
- are integrating our drug trial with a PG study evaluating whether buspirone response is related to expression of genes involved in serotoninergic neurotransmission
- will assess these variables together with in vivo assessment of serotonin synthesis capacity with PET.
This is a prospective, randomized, double blind, crossover study where children will be stratified by age into two groups. Treatment will last for 12 weeks with dosing twice a day. Parent ratings, cognitive tests and blood sampling will occur throughout the study period.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy|
|Study Start Date :||March 2004|
|Study Completion Date :||August 2005|
- Safety will be measured by obtaining clinical laboratory tests, vital signs and evaluating probably or definitely related adverse events.
- Population pharmacokinetics will be conducted to measure plasma concentrations in relation to the drug responses to buspirone.
- The primary efficacy outcome will be the overall severity score from the Clinical Global Impressions assessment obtained from two raters, (parent and examiner)
- Comparisons of allele, and genotype frequencies between responders and non-responders will be done for each polymorphism using Fisher's exact test to best predict response to buspirone.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00166621
|United States, Michigan|
|PET Center/Children's Hospital of Michigan|
|Detroit, Michigan, United States, 48201|